Clinical trial
Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
NCT00116454 · ANRS, Emerging Infectious Diseases, Other · Completed
Key facts
| NCT number | NCT00116454 |
|---|---|
| Title | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis |
| Official title | A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis |
| Acronym | Lipiocis |
| Lead sponsor | ANRS, Emerging Infectious Diseases, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular, Hepatitis, Viral, Human |
| Intervention type | Drug |
| Interventions | 131 I-lipiodol |
| Enrollment | 73 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Jun 30, 2005 |
| Last update posted | Sep 23, 2013 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: